December 5, 2017
CorMedix announced the acceptance of the final results of their observational post-marketing study of Neutrolin for publication in the peer-reviewed...
September 12, 2017
CorMedix announced its chief scientific officer Dr. Antony Pfaffle will present at an upcoming biotech conference.
August 17, 2017
CorMedix secured a research grant from the National Institutes of Health to expand the Company's antimicrobial hydrogel medical device program.
August 2, 2017
CorMedix shared an update to shareholders on their phase 3 clinical program for Neutrolin regarding a favorable correspondence with the...
July 12, 2017
CorMedix provided an update on its pre-clinical and clinical development programs to shareholders.
June 12, 2017
CorMedix announced changes to its board of directors in the upcoming weeks.
May 9, 2017
CorMedix released results from a test of taurolidine, an anti-infective component of Neutrolin, against a fungus illness called Candida auris.